Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1948 1
1958 1
1959 1
1960 1
1967 1
1968 1
1979 1
1981 3
1982 4
1983 6
1984 2
1985 9
1986 2
1987 6
1988 5
1989 4
1990 7
1991 4
1992 2
1993 3
1994 6
1995 5
1996 7
1997 5
1998 4
1999 4
2000 1
2001 3
2002 4
2003 10
2004 3
2005 4
2006 9
2007 8
2008 10
2009 15
2010 13
2011 14
2012 9
2013 9
2014 6
2015 5
2016 2
2017 3
2018 4
2019 3
2020 2
2022 1
2023 2
2024 1
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

220 results

Results by year

Filters applied: . Clear all
Page 1
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Citron ML, et al. Among authors: hurd d. J Clin Oncol. 2003 Apr 15;21(8):1431-9. doi: 10.1200/JCO.2003.09.081. Epub 2003 Feb 13. J Clin Oncol. 2003. PMID: 12668651 Clinical Trial.
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, Medvedova E, McCarthy PL, Libby EN, Voorhees PM, Orlowski RZ, Anderson LD Jr, Zonder JA, Milner CP, Gasparetto C, Agha ME, Khan AM, Hurd DD, Gowin K, Kamble RT, Jagannath S, Nathwani N, Alsina M, Cornell RF, Hashmi H, Campagnaro EL, Andreescu AC, Gentile T, Liedtke M, Godby KN, Cohen AD, Openshaw TH, Pasquini MC, Giralt SA, Kaufman JL, Yee AJ, Scott E, Torka P, Foley A, Fulciniti M, Hebert K, Samur MK, Masone K, Maglio ME, Zeytoonjian AA, Nadeem O, Schlossman RL, Laubach JP, Paba-Prada C, Ghobrial IM, Perrot A, Moreau P, Avet-Loiseau H, Attal M, Anderson KC, Munshi NC; DETERMINATION Investigators. Richardson PG, et al. Among authors: hurd dd. N Engl J Med. 2022 Jul 14;387(2):132-147. doi: 10.1056/NEJMoa2204925. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35660812 Free PMC article. Clinical Trial.
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators. Dimopoulos MA, et al. Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5. Lancet Oncol. 2016. PMID: 26671818 Free article. Clinical Trial.
Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption.
Morder KM, Nguyen M, Wilfahrt DN, Dahmani ZL, Burr ABP, Xie B, Morikone M, Nieves-Rosado H, Gunn WG, Hurd DE, Wang H, Mullett SJ, Bossong K, Gelhaus SL, Rajasundaram D, Kane LP, Delgoffe GM, Das J, Davar D, Overacre-Delgoffe AE. Morder KM, et al. Among authors: hurd de. Cancer Discov. 2025 Nov 3;15(11):2278-2297. doi: 10.1158/2159-8290.CD-25-0247. Cancer Discov. 2025. PMID: 40742298 Free PMC article.
Tubulins in C. elegans.
Hurd DD. Hurd DD. WormBook. 2018 Aug 4;2018:1-32. doi: 10.1895/wormbook.1.182.1. WormBook. 2018. PMID: 29381886 Free PMC article. Review.
The Microbiome in Advanced Melanoma: Where Are We Now?
Fortman DD, Hurd D, Davar D. Fortman DD, et al. Among authors: hurd d. Curr Oncol Rep. 2023 Sep;25(9):997-1016. doi: 10.1007/s11912-023-01431-3. Epub 2023 Jun 3. Curr Oncol Rep. 2023. PMID: 37269504 Free PMC article. Review.
WormBase: A Model Organism Database.
Dubaj Price M, Hurd DD. Dubaj Price M, et al. Among authors: hurd dd. Med Ref Serv Q. 2019 Jan-Mar;38(1):70-80. doi: 10.1080/02763869.2019.1548896. Med Ref Serv Q. 2019. PMID: 30942676
Zinc availability in the tumor microenvironment dictates anti-PD1 response in CDKN2A Low tumors via increased macrophage phagocytosis.
Buj R, Cole AR, Danielson J, Xu J, Hurd D, Kishore A, Kedziora KM, Chen J, Yang B, Barras D, Uboveja A, Amalric A, Apiz Saab JJ, Wickramasinghe J, Tangudu NK, Levasseur E, Wang H, Minasyan A, Dadey RE, Sharrow AC, Kunning S, Vendetti FP, Rivadeneira DB, Bakkenist CJ, Bruno TC, Delgoffe GM, Hempel N, Snyder NW, Bao R, Soloff AC, Kirk-Wood JM, Dangaj Laniti D, Kossenkov AV, Muir A, Das J, Davar D, Mesaros C, Aird KM. Buj R, et al. Among authors: hurd d. bioRxiv [Preprint]. 2025 Aug 5:2025.02.08.637227. doi: 10.1101/2025.02.08.637227. bioRxiv. 2025. PMID: 39975044 Free PMC article. Preprint.
Complex metal alkyls.
HURD DT. HURD DT. J Org Chem. 1948 Sep;13(5):711-3. doi: 10.1021/jo01163a015. J Org Chem. 1948. PMID: 18884416 No abstract available.
Kinesins in the nervous system.
Martin MA, Hurd DD, Saxton WM. Martin MA, et al. Among authors: hurd dd. Cell Mol Life Sci. 1999 Oct 15;56(3-4):200-16. doi: 10.1007/s000180050422. Cell Mol Life Sci. 1999. PMID: 11212348 Free PMC article. Review.
220 results